Medical device innovation demands time, evidence – and smart capital.

Swissrehamed GmbH has invested years of research and patient-focused development into robotic aquatic therapy systems such as ascros™, craPos™, and cranos™. These technologies offer value not just for patients and therapists – but also for investors who believe in long-term, purpose-driven health innovation.

We welcome partners who:
• value mid- and long-term impact over short-term speculation
• believe in real-world clinical value and patient-perceived outcomes
• are open to radically new financing models beyond the conventional startup pitch cycle

Our journey has led us to rethink how innovation is valued – not just in terms of IRR or DCF, but through a concept we call:

IPV – Investor Perceived Value,
inspired by PPV (Patient), DPV (Doctor) and TPV (Therapist) frameworks.

If you are interested in this next-generation venture logic –
driven by health equity, research-backed solutions and stakeholder alignment –
we invite you to explore our thinking:

→ Read the story: Looking for new ways in funding a great solution
→ Join the mission and help shape the next financing chapter of Swissrehamed.

🌍 Ascros Inc. – U.S. Spin-off for Global Scaling

Ascros Inc. is a U.S.-based spin-off of Swissrehamed GmbH, legally incorporated in Delaware and strategically operating from Boston, Massachusetts.

The company is built to:

• Scale the ascros™ system as a modular, FDA-aligned Class IIb robotic rehabilitation device
  
  

• Launch and operate NAMRU (Neurological Aqua Mobile Research Unit) for clinical trials in underserved regions
  
  

• Extend the reach of Swiss innovation to U.S. patients, hospitals, and research centers
  
  

🏛 Legal & Strategic Setup

Incorporation
• Location: Delaware, USA
• Entity: Ascros Inc. (C‑Corp)

U.S. Operating Base
• Location: Boston, Massachusetts
• Entity: Ascros Inc. (Boston Office)

IP Origin & Licensing Base
• Location: Switzerland
• Entity: Swissrehamed GmbH

💡 Why This Structure?

✅ Delaware is the U.S. standard for startup-friendly legal frameworks, investor onboarding, and equity instruments (SAFE, convertible notes).
✅ Boston offers access to top-tier rehabilitation centers, venture ecosystems, and university collaborators (e.g., MIT, MGH, Spaulding).
✅ IP remains protected under Swiss law while licensed to Ascros Inc. for commercialization.

🎯 How Investors Can Participate

Swiss and international investors are invited to join via:

• LVC-SAFE convertible notes (Liechtenstein cooperative framework)
  
  

• Strategic equity rounds in Ascros Inc. (Delaware C-Corp)
  
  

🧩 All modules (ascros™, NAMRU, ECP-UGC™) are prepared for FDA and MDR pathways, backed by a robust IP and regulatory strategy.